Ursofalk 250 mg capsules, hard  България - български - Изпълнителна агенция по лекарствата

ursofalk 250 mg capsules, hard 

dr.falk pharma gmbh - Урсодезоксихолевая киселина - 250 mg capsules, hard 

Coldrex MaxGrip Lemon  1000 mg/10 mg/40 mg powder for oral solution България - български - Изпълнителна агенция по лекарствата

coldrex maxgrip lemon  1000 mg/10 mg/40 mg powder for oral solution

glaxosmithkline consumer healthcare, glaxosmithkline export ltd - Парацетамол, аскорбинова киселина, Фенилэфрин - 1000 mg/10 mg/40 mg powder for oral solution

Strepsils Honey and Lemon 1,2 mg/0,6 mg lozenges България - български - Изпълнителна агенция по лекарствата

strepsils honey and lemon 1,2 mg/0,6 mg lozenges

reckitt benckiser healthcare international ltd. - АНТИСЕПТИЦИ И ДЕЗИНФЕКТАНТИ - 1,2 mg/0,6 mg lozenges

Coldrex HotRem Lemon 750 mg/10 mg/60 mg powder for oral solution България - български - Изпълнителна агенция по лекарствата

coldrex hotrem lemon 750 mg/10 mg/60 mg powder for oral solution

glaxosmithkline consumer healthcare, glaxosmithkline export ltd - Парацетамол, комбинации без. психолептиков - 750 mg/10 mg/60 mg powder for oral solution

Imfinzi Европейски съюз - български - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).